Chlamydia trachomatis ᰔ Sexually transmitted diseases (STDs), including urethritis caused by gonococcus and Chlamydia trachomatis, are of increasing public health importance (1, 3, 6, 7, 9) . The common occurrence of coinfections and the emergence of antimicrobial resistance of both pathogens emphasize the need for a single broadly active drug for management of these STDs (2, 3, 7, 9, (11) (12) (13) . Penicillins and other beta-lactam agents effective against susceptible gonococci are ineffective against chlamydia. However, fluoroquinolones and macrolides provide broad coverage for both pathogens, but the emergence of gonococcal resistance within these classes limits their utility (2, 3, 9, (11) (12) (13) . Early descriptions of the in vitro spectrum of activity of fusidic acid indicated the susceptibility of a limited number of Neisseria gonorrhoeae isolates (MIC range of 0.40 to 0.89 g/ ml) (8). This report examines the in vitro susceptibility of recent isolates of N. gonorrhoeae and C. trachomatis to fusidic acid (CEM-102; sodium fusidate), a potential alternative therapy for use in this clinical setting.
The MIC 90 of fusidic acid against these N. gonorrhoeae isolates was only 1 g/ml. According to the MIC 50 (0.5-g/ml) results, fusidic acid was 2-fold more active than penicillin and tetracycline (MIC 50 , 1 g/ml) but slightly less potent than azithromycin (MIC 50 , 0.25 g/ml). Fusidic acid was active against all strains of N. gonorrhoeae tested at Յ2 g/ml.
Ten isolates of C. trachomatis, including standard isolates from the ATCC (E-BOUR, F-IC-CAL3, C-HAR32, J-UW-36, L2434, D-UW-57kx, and B-HAR-36) and recent clinical isolates N18 (cervical), N19 (cervical), and 7015 (infant eye), were selected for study. Susceptibility testing was performed with cell culture by use of HEp-2 cells (13) at State University of New York, Downstate Medical Center (Brooklyn, NY).
The activity of fusidic acid against C. trachomatis was compared with those of azithromycin, clarithromycin, telithromycin, and doxycycline ( Table 2 ). The MIC range of fusidic acid against C. trachomatis was 0.12 to 0.5 g/ml, with identical fusidic acid MBC 90 and MIC 90 values for this organism of 0.5 g/ml. The MIC 90 values for azithromycin, clarithromycin, telithromycin, and doxycycline were 0.12, 0.06, 0.06, and 0.06 g/ml, respectively, each 2-to 4-fold lower than that for fusidic acid.
These in vitro testing data suggest that fusidic acid may be considered an alternative treatment for multidrug-resistant N. gonorrhoeae strains and could provide an advantage for treatment of STD as a single agent targeting both gonococcus and C. trachomatis (1, 3, 7, 9) . The pharmacokinetics of fusidic acid has recently been modeled to define safe highdose regimens designed to attenuate selection of resistance that was reported for doses originally approved for clinical use in Europe and Australia as well as to maximize potency versus cutaneous infection pathogens such as Staphylococcus aureus (10, 14) . These modified dosing schedules achieve fusidic acid trough plasma levels of ca. 80 g/ml, representing 40-to 160-fold-greater concentrations than the highest N. gonorrhoeae or C. trachomatis MIC result found in this report (8, 10, 14) . However, fusidic acid urinary tract concentrations are limited. Further investigations of fusidic acid are needed to determine its potential role for STDs caused by these two pathogens. 
